Aurélien Justet, Mada Ghanem, Tiara Boghanim, Mouna Hachem, Eirini Vasarmidi, Madeleine Jaillet, Aurélie Vadel, Audrey Joannes, Pierre Mordant, Philippe Bonniaud, Martin Kolb, Lei Ling, Aurélie Cazes, Hervé Mal, Arnaud Mailleux, Bruno Crestani
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic possibilities. FGF19 (fibroblast growth factor 19), an endocrine FGF, was recently shown to decrease liver fibrosis. To ask whether FGF19 had antifibrotic properties in the lung and decipher its effects on common features associated with lung fibrogenesis, we assessed, by ELISA, FGF19 concentrations in plasma and BAL fluids obtained from control subjects and patients with IPF. In vivo , using an intravenously administered adeno11-associated virus, we overexpressed FGF19 at the fibrotic phase of two experimental models of murine lung fibrosis and assessed its effect on lung morphology, lung collagen content, fibrosis markers, and profibrotic mediator expression at mRNA and protein levels...
August 2022: American Journal of Respiratory Cell and Molecular Biology